Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Share:
Related ABT
Benzinga's Top Upgrades, Downgrades For August 17, 2017
Lightning Round: Jim Cramer Shares His Thoughts On Freeport-McMoRan, Pfizer And More

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Latest Ratings for ABT

DateFirmActionFromTo
Aug 2017CitigroupInitiates Coverage OnNeutral
Jul 2017ArgusMaintainsBuy
Jul 2017Deutsche BankMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!